Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项随机、双盲、安慰剂对照评价舒非尼酮(SC1011)片在特发性肺纤维化(IPF)患者中的有效性和安全性的II/III期临床研究
[Translation] A randomized, double-blind, placebo-controlled phase II/III clinical study to evaluate the efficacy and safety of sufenidone (SC1011) tablets in patients with idiopathic pulmonary fibrosis (IPF)
主要目的:评价舒非尼酮(SC1011)片治疗IPF的疗效
次要目的:评价舒非尼酮(SC1011)片治疗IPF患者的其他疗效
[Translation] Primary purpose: To evaluate the efficacy of sufenidone (SC1011) tablets in the treatment of IPF
Secondary purpose: To evaluate other efficacy of sufenidone (SC1011) tablets in the treatment of IPF patients
研究评估SC1011片对健康成人志愿者的耐受性、药代动力学特征
[Translation] Study to evaluate the tolerability and pharmacokinetic characteristics of SC1011 tablets in healthy adult volunteers
主要目的:评估健康成人单次剂量递增和多次剂量递增口服SC1011片的安全性和耐受性。
次要目的:评估进食对健康成人单次口服SC1011片药代动力学的影响。
[Translation] Primary objective: To evaluate the safety and tolerability of single ascending dose and multiple ascending dose oral administration of SC1011 tablets in healthy adults.
Secondary objective: To evaluate the effect of food intake on the pharmacokinetics of single oral administration of SC1011 tablets in healthy adults.
100 Clinical Results associated with Wuxi Zhikang Hongren New Drug Development Co., Ltd.
0 Patents (Medical) associated with Wuxi Zhikang Hongren New Drug Development Co., Ltd.
100 Deals associated with Wuxi Zhikang Hongren New Drug Development Co., Ltd.
100 Translational Medicine associated with Wuxi Zhikang Hongren New Drug Development Co., Ltd.